Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer

Journal of the National Medical Association

Volumn 96, Issue 12, 2004, Pages 1587-1593

  Wyatt, Reena B ^a   Sánchez Ortiz, Ricardo F ^a   Wood, Christopher G ^a   Ramirez, Edilberto ^a   Logothetis, Christopher ^a   Pettaway, Curtis A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Advanced prostate cancer; Androgen independent; Race

Indexed keywords

ALKALINE PHOSPHATASE; ANDROGEN; ANGIOGENESIS INHIBITOR; DACTINOMYCIN; DOXORUBICIN; ESTRAMUSTINE; FLUOXETINE; FLUTAMIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; HEMOGLOBIN; INTERFERON; KETOCONAZOLE; MITOMYCIN C; PACLITAXEL; PREDNISONE; STRONTIUM; SURAMIN; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ANTIGEN SPECIFICITY; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CAUCASIAN; CHILD; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; HEMOGLOBIN DETERMINATION; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SURVIVAL; TIME SERIES ANALYSIS;

AFRICAN AMERICANS; AGED; EUROPEAN CONTINENTAL ANCESTRY GROUP; HISPANIC AMERICANS; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 10344249957     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Morton Jr RA. Racial differences in adenocarcinoma of the prostate in North American men. Urology. 1994;44:637-645.
2. Cersosimo RJ, Carr D. Prostate cancer: current and evolving strategies. Am J Health Syst Pharm. 1996;53:381-396; quiz 446-448.
3. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
4. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33.
5. Fowler Jr JE, Bigler SA, Bowman G, et al. Race and cause-specific survival with prostate cancer: influence of clinical stage, Gleason score, age and treatment. J Urol. 2000;163:137-142.
6. Optenberg SA, Thompson IM, Friedrichs P, et al. Race, treatment and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA. 1995;274:1599-1605.
7. Logothetis CJ, Samuels ML, von Eschenbach AC, et al. Doxorubicin, mitomycin-C and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J Clin Oncol. 1983;1:368-379.
8. Soloway MS, Ishikawa S, van der Zwaag R, et al. Prognostic factors in patients with advanced prostate cancer. Urology. 1989;33:53-56.
9. Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999;17:948-957.
10. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195-202.
11. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
12. Miller B, Kolonel L, Bernstein L, et al. Racial/Ethnic Patterns of Cancer in the United States 1988-1992. Vol. NIH Pub. No. 96-4104. Bethesda: National Cancer Institute, 1996.
13. Cox D. Regression models and lifetables. JR Stat Soc B. 1972;34:187-220.
14. Brawn PN, Johnson EH, Kuhl DL, et al. Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer. 1993;71: 2569-2573.
15. McLeod DG, Schellhammer PF, Vogelzang NJ, et al. Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. Prostate. 1999;40:218-24.
16. Fowler JE, Bigler SA, Renfroe DL, et al. Prostate-specific antigen in black and white men after hormonal therapies for prostate cancer. J Urol. 1997; 158:150-154.
17. 2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol. 1994;21:613-619.
18. Thompson I, Tangen C, Tolcher A, et al. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst. 2001;93:219-225.
19. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003;169:164-169.
20. Mebane C, Gibbs T, Horm, J. Current status of prostate cancer in North American black males. J Natl Med Assoc. 1990;82:782-788.
21. Sakr WA, Grignon DJ, Haas GP, et al. Epidemiology of high-grade prostate intraepithelial neoplasia. Pathol Res Pract. 1995;191:838-841.
22. Pettaway CA, Troncoso P, Ramirez EI, et al. Prostate-specific antigen and pathologic features in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998;160:437-442.
23. Pettaway CA. Racial differences in the androgen/androgen receptor pathway in prostate cancer. J Natl Med Assoc. 1999;91:653-660.
24. Bianco FJ, Fischer MB, Cher ML, et al. Androgen metabolism genotypes as predictors of PSA progression and first-line hormonal deprivation failure. J Urol. 2004;171:suppl. 1664a.
25. Powell IJ, Schwartz K, Hussain M. Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system. Urology. 1995;46:825-830.
26. Hoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001;93:388-395.